MEK Inhibitor News and Research

RSS
CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

New research suggests potential role for MEK inhibitors in type 2 diabetes

New research suggests potential role for MEK inhibitors in type 2 diabetes

Study reports anti-cancer activity in mice treated with experimental drug TAK-733

Study reports anti-cancer activity in mice treated with experimental drug TAK-733

Researchers develop mouse model that reproduces most typical features of Noonan syndrome

Researchers develop mouse model that reproduces most typical features of Noonan syndrome

Cancer Network presents exclusive coverage of ESMO 2014 Congress

Cancer Network presents exclusive coverage of ESMO 2014 Congress

Combination treatment prevents disease progression in patients with advanced melanoma

Combination treatment prevents disease progression in patients with advanced melanoma

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy achieves greater progression-free survival, response rates in melanoma

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Study describes new tack in treatment of lung adenocarcinomas

Study describes new tack in treatment of lung adenocarcinomas

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Researchers identify two novel BRAF fusions in melanomas

Researchers identify two novel BRAF fusions in melanomas

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.